A Phase 3, Multicenter, Open Label Study to Test the Diagnostic performance of Copper Cu 64 PSMA I&T PET/CT in staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk, or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
Inclusions/Exclusions:
– Must have planned prostatectomy with ePLND
– Treatment with ADT, Neoadjuvant chemotherapy, radiation therapy (including local ablation techniques) or any investigational therapy prior to prostatectomy is not allowed.
– Patients who had PET-PSMA as part of their standard medical care within 90 days prior to enrollment are excluded.
Learn more here.